Concepedia

Michael Lukason

ML

Statistics

Publications

17

Citations

1.3K

H-Index

15

Active since

1997

Affiliations

Framingham State University(Current)

Sanofi (United States)

University of Florida

Sanofi (France)

Charles River Laboratories (United States)

Michael Lukason is an author at Framingham State University specializing in molecular biology, life sciences, and gene therapy.

Publications per year

1997–2021

17

Publications

17

CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10

Guo-Xiang Ruan, Elizabeth Barry, Dan Yu et al. · Molecular Therapy · 2017 · 272 citations · Full text

, , +17

Preclinical Safety Evaluation of AAV2-sFLT01— A Gene Therapy for Age-related Macular Degeneration

Timothy K. MacLachlan, Michael Lukason, Margaret E. Collins et al. · Molecular Therapy · 2010 · 167 citations · Full text

, , +15

Preexisting Immunity and Low Expression in Primates Highlight Translational Challenges for Liver-directed AAV8-mediated Gene Therapy

Gregory D Hurlbut, Robin J. Ziegler, Jennifer B. Nietupski et al. · Molecular Therapy · 2010 · 138 citations · Full text

, , +13

Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization

Peter Pecháň, Hillard Rubin, Michael Lukason et al. · Gene Therapy · 2008 · 106 citations

, , +16

A Concentrated and Stable Aerosol Formulation of Cationic Lipid:DNA Complexes Giving High-Level Gene Expression in Mouse Lung

Simon J. Eastman, Michael Lukason, Jennifer D. Tousignant et al. · Human Gene Therapy · 1997 · 89 citations

, , +17

1–5 of 17